U.S. health officials have authorized the first nasal spray to manage severe allergic reactions, providing an alternative to injectable products like EpiPen. The Food and Drug Administration has given the green light to the nasal spray created by ARS Pharmaceuticals Inc. for use as an emergency treatment for adults and older children facing life-threatening allergic reactions known as anaphylaxis. This spray is designed for individuals weighing at least 66 pounds.
Anaphylaxis happens when the body’s immune system reacts suddenly and unexpectedly to a foreign substance, such as food, insect stings, or medications. Symptoms of anaphylaxis include hives, swelling, itching, vomiting, and breathing difficulties.
The nasal spray, named Neffy, is among various needle-free devices in development to assist the estimated 33 million to 45 million Americans with severe allergies to food and other triggers. Neffy is administered in a single dose sprayed into one nostril.
